Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-01-14T19:34:23.771Z Has data issue: false hasContentIssue false
  • English
  • Français

Clinical Practice Regarding Dopamine-Agonist Use and Driving in Parkinson's Disease

Published online by Cambridge University Press:  02 December 2014

R. M.A. de Bie ,
J. Miyasaki ,
A. E. Lang  and
S. H. Fox
R. M.A. de Bie
Affiliation:
Movement Disorders Centre, Division of Neurology, University of Toronto, Toronto, Ontario, Canada Department of Neurology, Academic Medical Center, Amsterdam, The Netherlands
J. Miyasaki
Affiliation:
Movement Disorders Centre, Division of Neurology, University of Toronto, Toronto, Ontario, Canada
A. E. Lang
Affiliation:
Movement Disorders Centre, Division of Neurology, University of Toronto, Toronto, Ontario, Canada
S. H. Fox
Affiliation:
Movement Disorders Centre, Division of Neurology, University of Toronto, Toronto, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Current Health Canada instructions for use of the dopamine agonists (DA), pramipexole and ropinirole, state that Parkinson's disease (PD) patients should be told not to drive. The objective was to assess neurologists' actual clinical practice concerning driving advice they give to PD patients starting a DA.

Methods:

An online survey was created consisting of 4 items regarding demographics, 5 regarding PD and driving, and 9 regarding DA use and driving. The survey was distributed to 563 neurologists.

Results:

In total 96 neurologists (17.9%) responded. 4.4% tell patients with PD not to drive, solely because they are taking a DA. Respondents assess the patient's tendency for excessive daytime sleepiness and sleep attacks after starting a DA more frequently than after starting other dopaminergic drugs (p<0.001).

Discussion:

A minor proportion of the clinicians responding to our survey advise PD patients not to drive, solely because they use a DA. Such being the case, we propose that current Health Canada guidelines need revision.

Résumé:

RÉSUMÉ: <span class='italic'> <span class='bold'>Contexte</span></span>:

Les directives de Santé Canada concernant l’utilisation des agonistes de la dopamine (AD),soit le pramipexole et le ropinirole, mentionnent qu’on devrait dire aux patients atteints de la maladie de Parkinson (MP) de ne pas conduire s‘ils prennent ces médicaments. Le but de cette étude était de vérifier ce que les neurologues conseillent en clinique à leurs patients atteints de la MP lorsqu’ils commencent à prendre un AD.

<span class='italic'> <span class='bold'>Méthodes</span></span>:

Nous avons effectué une enquête par courrier électronique dont 4 items portaient sur la démographie, 5 sur la MP et la conduite automobile, et 9 sur l’utilisation d’un AD et la conduite automobile. Le questionnaire a été envoyé à 563 neurologues.

<span class='italic'> <span class='bold'>Résultats</span></span>:

96 neurologues ont répondu au questionnaire (17,9%). Parmi eux, 4,4% disent à leurs patients atteints de la MP de ne pas conduire parce qu’ils prennent un AD. Les répondants vérifient plus souvent si les patients ont tendance à présenter une somnolence diurne excessive et des attaques de sommeil lorsqu’ils commencent à prendre un AD plutôt qu’un autre médicament dopaminergique (p > 0,001).

<span class='italic'> <span class='bold'>Discussion</span></span>:

Une faible proportion des cliniciens qui ont participé à notre enquête prévient leurs patients de ne pas conduire simplement parce qu’ils prennent un AD. Devant cet état de fait, nous suggérons que les lignes directrices actuelles devraient être révisées.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 34 , Issue 4 , November 2007 , pp. 438 - 442
Copyright
Copyright © The Canadian Journal of Neurological 2007

References

1. Moller, H. Antiparkinsonian drugs and “sleep attacks.” Canadian ADR newsletter. 2001;11:3–4.Google Scholar
2. Frucht, S, Rogers, JD, Greene, PE, Gordon, MF, Fahn, S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology. 1999;52:1908–10.CrossRefGoogle ScholarPubMed
3. Olanow, CW, Schapira, AHV, Roth, T. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole [letter]. Neurology. 2000;54:274.CrossRefGoogle Scholar
4. Weiner, WJ. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole [letter]. Neurology. 2000;54:274–5.Google Scholar
5. Uc, EY, Rizzo, M, Anderson, SW, Sparks, JD, Rodnitzky, RL, Dawson, JD. Impaired visual search in drivers with Parkinson’s disease. Ann Neurol. 2006;60:407–13.CrossRefGoogle ScholarPubMed
6. Homann, CN, Suppan, K, Homann, B, Crevenna, R, Ivanic, G, Ruzicka, E. Driving in Parkinson’s disease — a health hazard? J Neurol. 2003;250:1439–46.CrossRefGoogle ScholarPubMed
7. Ritter, G, Steinberg, H. Parkinsonism and driving fitness. Munch Med Wochenschr. 1979;121:1329–30.Google Scholar
8. Bassi, S, Albizzati, MG, Frattola, L, Passerini, D, Trabucchi, M. Dopamine receptors and sleep induction in man. J Neurol Neurosurg Psychiatry. 1997;42:458–60.CrossRefGoogle Scholar
9. Ferreira, JJ, Galitzky, M, Thalamas, C, Tiberge, M, Montastruc, JL, Sampaio, C, et al. Effect of ropinirole on sleep onset: a randomized placebo controlled study in healthy volunteers. Neurology. 2002;58:460–2.CrossRefGoogle ScholarPubMed
10. Gjerstad, MD, Alves, G, Wentzel-Larsen, T, Aarsland, D, Larsen, JP. Excessive daytime sleepiness in Parkinson disease. Is it the drug or the disease? Neurology. 2006;67:853–8.CrossRefGoogle ScholarPubMed
11. Hobson, DE, Lang, AE, Martin, WRW, Razmy, A, Rivest, J, Fleming, J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease. A survey by the Canadian Movement Disorders Group. JAMA. 2002;287:455–63.CrossRefGoogle ScholarPubMed
12. Clarenbach, P. ParkinsonCJN34_4prd.xml 8-Oct-2014 11:26:24a 3,081 S0317167100007241jxx.xml 7-Oct-2014 2:52:14p 5,929 S0317167100007253jed.xml 29-Oct-2014 4:08:52p 34,392 S0317167100007265jrv.xml 29-Oct-2014 4:09:26p 23,101 S031716712019;s disease and sleep. J Neurol. 2000;247(Suppl):20–3.CrossRefGoogle Scholar
13. Schafer, D, Greulich, W. Effects of parkinsonian medication on sleep. J Neurol. 2000;247 Suppl:24–7.CrossRefGoogle ScholarPubMed
14. Bowen, FP, Kamienny, RS, Burns, MM, Yahr, M. Parkinsonism: effects of levodopa treatment on concept formation. Neurology. 1975;25:701–4.CrossRefGoogle ScholarPubMed
15. Downes, JJ, Roberts, AC, Sahakian, BJ, Evenden, JL, Morris, RG, Robbins, TW. Impaired extra-dimensial shift performance in medicated and unmedicated ParkinsonCJN34_4prd.xml 8-Oct-2014 11:26:24a 3,081 S0317167100007241jxx.xml 7-Oct-2014 2:52:14p 5,929 S0317167100007253jed.xml 29-Oct-2014 4:08:52p 34,392 S0317167100007265jrv.xml 29-Oct-2014 4:09:26p 23,101 S031716712019;s disease: evidence for a specific attentional dysfunction. Neuropsychologia. 1989;27:1329–43.CrossRefGoogle Scholar
16. Kulisevsky, J, Garcia-Sanchez, C, Berthier, ML, Barbanoj, M, Pascual-Sedano, B, Gironell, A, et al. Chronic effects of dopaminergic replacement on cognitive function in ParkinsonCJN34_4prd.xml 8-Oct-2014 11:26:24a 3,081 S0317167100007241jxx.xml 7-Oct-2014 2:52:14p 5,929 S0317167100007253jed.xml 29-Oct-2014 4:08:52p 34,392 S0317167100007265jrv.xml 29-Oct-2014 4:09:26p 23,101 S031716712019;s disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000;15:613–26.3.0.CO;2-F>CrossRefGoogle Scholar
17. Nabi, H, Guéguen, A, Chiron, M, Lafont, S, Zins, M, Lagarde, E. Awareness of driving while sleepy and road traffic accidents: prospective study in GAZEL cohort. BMJ. 2006;333:75–7.CrossRefGoogle ScholarPubMed